Zealand Pharma A/S
ZLDPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -81.7% | 229.6% | -64.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 87.4% | 94.4% | 70.5% | 59.4% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -2,029.3% | -166.9% | -785.3% | -359% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | -$0 | -$0 | -$0 | -$0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -1,720.9% | -205.3% | -928.6% | -348% |
| EPS | -16.24 | -12.44 | -20.9 | -23.75 |
| % Growth | -30.5% | 40.5% | 12% | – |
| EPS Diluted | -16.24 | -12.44 | -20.9 | -23.75 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$1 | -$1 | -$1 | -$1 |
| % Margin | -1,632.7% | -191.9% | -639.8% | -243.3% |